Tuberculosis Mark Oette Klinik für Allgemeine Innere Medizin, Gastroenterologie und Infektiologie Krankenhaus der Augustinerinnen, Köln
Conflicts • This presentation is free of financial interests • Speech honoraria of the last 3 years BMS Falk Gilead Heinen & Löwenstein Hitachi Krankenhäuser
Tbc worldwide
Europe: Transm issible Diseases Inzidence-based DALY/ 100.000, 2009-2013 (1.4 Mio, every 14th person) Cassini A. Eurosurveillance 2018; 23: pii= 17.00454
Europe: Tbc Notification Rate
Tuberculosis Incidence Germany (RKI 2018)
Lung Tbc and Nationality (RKI 2015)
Nationality: Italy
Tuberculosis, Age, and Gender (RKI 2018)
Diagnostics (RKI 2015)
Mortality (RKI 2018)
Resistance (RKI 2018)
Resistance: Italy
Resistance (RKI 2018)
Lange C, et al. Respirology 2018; 23: 656-673
Resistance (MDR)
Europe: Tbc MDR-Rate
Sequencing for Resistance Mutations • Evaluation of 5 software tools to predict resistance (n= 211), 2014 • Comparison with growth cultures/ phenotypic resistance testing • WGS: Illumina MiSec System • Software tools : PhyResSE, Mykrobe Predictor, TB Profiler, TGS-TB and KvarQ • Results: Sensitivity: 74-80% ; Specificity: > 95% Considerable variation between individual drugs Turnaround time (median): 5 vs. 19 days Van Beek J. Clin Microbiol Infect 2019; 25: 82-86
Summary In Germany approx. 5500 affected persons, slow decline Epidemiology still driven by migrants Resistance: Significant problem, rising (not in G) Transmission of resistance MDR: Relevant for survival Resistance testing: Procession time suboptimal Molecular resistance testing: New applications underway The future: Resistance testing by NGS standard
Thank you !
Resistance
Recommend
More recommend